Rodman & Renshaw Initiates Coverage on BioAtla (NASDAQ:BCAB)

Investment analysts at Rodman & Renshaw started coverage on shares of BioAtla (NASDAQ:BCAB) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $4.00 price target on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research report on Friday. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioAtla currently has a consensus rating of “Hold” and a consensus target price of $4.00.

BioAtla Stock Performance

BCAB stock traded down $0.00 during trading on Tuesday, reaching $0.31. 4,305,481 shares of the company were exchanged, compared to its average volume of 2,499,553. BioAtla has a 52-week low of $0.24 and a 52-week high of $1.43. The company has a market cap of $18.22 million, a P/E ratio of -0.27 and a beta of 1.04. The stock’s 50 day moving average price is $0.74 and its 200 day moving average price is $0.61.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.04. As a group, equities research analysts forecast that BioAtla will post -1.46 EPS for the current year.

Institutional Trading of BioAtla

A number of hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP lifted its holdings in shares of BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares in the last quarter. Millennium Management LLC purchased a new position in BioAtla in the third quarter valued at about $235,000. Vanguard Group Inc. lifted its stake in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Sheets Smith Investment Management acquired a new position in shares of BioAtla during the third quarter worth about $46,000. Finally, Acorn Capital Advisors LLC boosted its position in shares of BioAtla by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock worth $1,915,000 after buying an additional 803,065 shares during the period. 77.23% of the stock is owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.